Nitric Oxide Attenuates the Expression of Transforming Growth Factor-β 3 mRNA in Rat Cardiac Fibroblasts via Destabilization
- 1 August 2001
- journal article
- other
- Published by Wolters Kluwer Health in Hypertension
- Vol. 38 (2) , 261-266
- https://doi.org/10.1161/01.hyp.38.2.261
Abstract
Transforming growth factor-β (TGF-β) has been implicated in the development of interstitial fibrosis in cardiac hypertrophy. NO has been regarded as a potent inhibitor of cardiac fibroblast growth, albeit the modulation of cellular events associated with interstitial fibrosis remains undefined. In this regard, the regulation of TGF-β mRNA expression by the NO donor S -nitroso- N -acetyl-penicillamine (SNAP) was examined in neonatal rat cardiac fibroblasts. SNAP treatment for 4 hours decreased TGF-β 3 mRNA levels, an effect mimicked by 8-bromo-cGMP. TGF-β 3 mRNA, however, had returned to levels observed in the untreated cells after a 24-hour exposure to SNAP, whereas a decreased expression persisted with 8-bromo-cGMP. In contrast to TGF-β 3 , TGF-β 1 mRNA levels were modestly increased in response to cGMP-generating molecules. The treatment with actinomycin D for at least 8 hours did not appreciably alter TGF-β 3 mRNA levels. By contrast, SNAP treatment caused a rapid decrease of TGF-β 3 mRNA with a half-life of 3.3±0.2 hours, thereby supporting a mechanism of destabilization. The pretreatment with SNAP inhibited angiotensin II-stimulated protein synthesis and the concomitant expression of TGF-β 3 mRNA. These data reveal a disparate pattern of TGF-β 1 and TGF-β 3 mRNA regulation by NO and highlight a novel mechanism of destabilization contributing to the decreased expression of TGF-β 3 mRNA. The modulation of both basal and angiotensin II-stimulated TGF-β 3 mRNA expression provides a mechanism by which NO may influence the progression of interstitial fibrosis.Keywords
This publication has 16 references indexed in Scilit:
- LU135252, an endothelinA receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarctionBritish Journal of Pharmacology, 2000
- Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-β1 and endothelin-1 from fibroblastsCardiovascular Research, 1998
- Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts.Journal of Clinical Investigation, 1998
- Control of Nitric Oxide Production by Transforming Growth Factor-β1: Mechanistic Insights and Potential Relevance to Human DiseaseNitric Oxide, 1997
- Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase.Journal of Clinical Investigation, 1995
- Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions.Hypertension, 1994
- Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β)Growth Factors, 1993
- Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteineJournal of the American College of Cardiology, 1990
- Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart FailureNew England Journal of Medicine, 1987
- Nitroglycerin Tolerance in Vitro: Effect on cGMP Turnover in Vascular Smooth MuscleActa Pharmacologica et Toxicologica, 1984